EACS2023: 596 Durability and schedule compliance to cabotegravir/rilpivirine long acting: a retrospective analysis N.B. Bana , L.F. Rezzonico , F. Peracchi , A. Raimondi , C. Moioli , L. Chianura , M. Puoti , R. Rossotti ASST Niguarda Great Metropolitan Hospital, Infectious Diseases Unit, Milan, Italy, University of Milano Bicocca, Milan, Italy, University of Pavia, Pavia, Italy General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Cabotegravir/rilpivirine long-acting (CARLA) is an important alternative to daily oral therapy for people living with HIV (PLHIV), but compliance to administration schedule might be an issue in real life. Aim of this study is to describe regime durability and users’ treatment schedule fulfillment over time. Method: Retrospective monocentric observational study including PLHIV who voluntarily switched to injectable CARLA since regimen availability. Demographic, clinical, and immuno-virologic data were collected. Treatment schedule delay for each administration, and number of reminder phone calls were registered. Descriptive and non-parametric statistics were used to depict study population. KM curves were estimated for regimen durability. Univariate/multivariate binary regression analysis was employed to describe factors associated to a better compliance. Results: The study enrolled 147 individuals: Table 1 shows clinical and demographic features. Table 1. Demographic and clinical features of study population (N=147) Male, n (%) 131 (89.1) Age, years, median (IQR) 47.3 (39.8-54.7) Italian born, n (%) 126 (85.7) Type of risk exposure, n (%) MSM 94 (63.9) MSW/WSM 41 (27.9) IVDU 11 (7.5) Other 1 (0.7) BMI, median (IQR) 24.4 (22.5-27.3) CDC C Stage at diagnosis, n (%) 34 (23.1) Length of infection, years, median (IQR) 10.7 (6.3-17.6) Number of previous therapeutic lines, median (IQR) 3 (2-4) Three-drugs regimens before switch, n (%) 37 (25.2) Baseline presence of any NNRTI-related RAMs, n (%) 10 (6.8) Baseline lymphocyte T CD4+, cell/mmc, median (IQR) 799 (557-1,053) Baseline CD4/CD8 ratio, median (IQR) 0.90 (0.65-1.23) Baseline HIV RNA, n (%) Target not detected 101 (68.7) Below the limit of quantification 23 (15.7) 20-200 copies/mL 20 (13.6) 200-1,000 copies/mL 3 (2.0) Baseline detectable HIV RNA, copies/mL, median (IQR) 38 (30-92) MSM: Men who have sex with men; MSW: Men who have sex with women; WSM: Women who have sex with men; IVDU: Intravenous drug users; BMI: Body Mass Index; IQR: Interquartile range; 3TC: Lamivudine; DTG: Dolutegravir; ABC: Abacavir; NNRTI: Non-nucleotide reverse transcriptase inhibitors; RAMs: (drug) Resistance-associated mutations. During a follow-up of 57.0 years, we registered 11 discontinuations (Figure 1), with an incidence of 19.3 per 100 PY (95% C.I. 10.2-33.5): 90.3% was still on treatment after 250 days. Main reasons for interruptions were: pain (4.1%), virologic failure (1.4%), transfer to another hospital (1.4%), allergic reaction (0.7 %). Delayed administrations were uncommon: at least one delay on treatment schedule was observed for 19.6% individuals, especially between Day 28 and Day 84 (second to third injection, p=0.008), although slight (Figure 2). Individuals who needed a reminder phone call were 5.8%, with a percentage between two following drug administration always <3% and a stable trend over time (p=0.983). With binary regression analysis, the only factor significantly associated to delayed administration was a previous two-drugs regimen before switch (OR 0.32, 95% CI 0.129-0.792, p=0.014). Conclusions: PLHIV treated with CARLA showed a good durability and an overall optimal schedule compliance with scarce need of phone call reminders. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1,2 1,3 1,2 1 1 1 1,2 1 1 2 3 137
RkJQdWJsaXNoZXIy Mzc2ODc=